{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T02:47:19Z","timestamp":1794624439248,"version":"4.9.1"},"reference-count":144,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The overactivation of the mineralocorticoid receptor (MR) promotes pathophysiological processes related to multiple physiological systems, including the heart, vasculature, adipose tissue and kidneys. The inhibition of the MR with classical MR antagonists (MRA) has successfully improved outcomes most evidently in heart failure. However, real and perceived risk of side effects and limited tolerability associated with classical MRA have represented barriers to implementing MRA in settings where they have been already proven efficacious (heart failure with reduced ejection fraction) and studying their potential role in settings where they might be beneficial but where risk of safety events is perceived to be higher (renal disease). Novel non-steroidal MRA have distinct properties that might translate into favourable clinical effects and better safety profiles as compared with MRA currently used in clinical practice. Randomised trials have shown benefits of non-steroidal MRA in a range of clinical contexts, including diabetic kidney disease, hypertension and heart failure. This review provides an overview of the literature on the systemic impact of MR overactivation across organ systems. Moreover, we summarise the evidence from preclinical studies and clinical trials that have set the stage for a potential new paradigm of MR antagonism.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1007\/s00125-023-06031-1","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T10:02:48Z","timestamp":1703152968000},"page":"246-262","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":62,"title":["Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists"],"prefix":"10.1007","volume":"67","author":[{"given":"Gianluigi","family":"Savarese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felix","family":"Lindberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerasimos","family":"Filippatos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan D.","family":"Anker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"issue":"12","key":"6031_CR1","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1038\/nm.1879","volume":"14","author":"S Shibata","year":"2008","unstructured":"Shibata S, Nagase M, Yoshida S et al (2008) Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Nat Med 14(12):1370\u20131376. https:\/\/doi.org\/10.1038\/nm.1879","journal-title":"Nat Med"},{"issue":"9","key":"6031_CR2","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1161\/CIRCULATIONAHA.107.708537","volume":"116","author":"E Ingelsson","year":"2007","unstructured":"Ingelsson E, Pencina MJ, Tofler GH et al (2007) Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. Circulation 116(9):984\u2013992. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.708537","journal-title":"Circulation"},{"issue":"24","key":"6031_CR3","doi-asserted-by":"publisher","first-page":"2604","DOI":"10.1161\/CIRCULATIONAHA.106.634626","volume":"114","author":"F Beygui","year":"2006","unstructured":"Beygui F, Collet JP, Benoliel JJ et al (2006) High plasma aldosterone levels on admission are associated with death in patients presenting with acute ST-elevation myocardial infarction. Circulation 114(24):2604\u20132610. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.634626","journal-title":"Circulation"},{"issue":"13","key":"6031_CR4","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.1161\/CIRCULATIONAHA.106.653964","volume":"115","author":"G G\u00fcder","year":"2007","unstructured":"G\u00fcder G, Bauersachs J, Frantz S et al (2007) Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure. Circulation 115(13):1754\u20131761. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.106.653964","journal-title":"Circulation"},{"issue":"2","key":"6031_CR5","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1093\/eurheartj\/ehaa736","volume":"42","author":"R Agarwal","year":"2021","unstructured":"Agarwal R, Kolkhof P, Bakris G et al (2021) Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J 42(2):152\u2013161. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa736","journal-title":"Eur Heart J"},{"issue":"10008","key":"6031_CR6","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams B, MacDonald TM, Morant S et al (2015) Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 386(10008):2059\u20132068. https:\/\/doi.org\/10.1016\/S0140-6736(15)00257-3","journal-title":"Lancet"},{"issue":"36","key":"6031_CR7","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M et al (2021) 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 42(36):3599\u20133726. https:\/\/doi.org\/10.1093\/eurheartj\/ehab368","journal-title":"Eur Heart J"},{"issue":"1","key":"6031_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H et al (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364(1):11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1009492","journal-title":"N Engl J Med"},{"issue":"10","key":"6031_CR9","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/nejm199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ et al (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 341(10):709\u2013717. https:\/\/doi.org\/10.1056\/nejm199909023411001","journal-title":"N Engl J Med"},{"issue":"14","key":"6031_CR10","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F et al (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348(14):1309\u20131321. https:\/\/doi.org\/10.1056\/NEJMoa030207","journal-title":"N Engl J Med"},{"issue":"5","key":"6031_CR11","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/ehv464","volume":"37","author":"SD Solomon","year":"2016","unstructured":"Solomon SD, Claggett B, Lewis EF et al (2016) Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction. Eur Heart J 37(5):455\u2013462. https:\/\/doi.org\/10.1093\/eurheartj\/ehv464","journal-title":"Eur Heart J"},{"key":"6031_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s10741-021-10077-x","author":"SJ Greene","year":"2021","unstructured":"Greene SJ, Tan X, Yeh YC et al (2021) Factors associated with non-use and sub-target dosing of medical therapy for heart failure with reduced ejection fraction. Heart Fail Rev. https:\/\/doi.org\/10.1007\/s10741-021-10077-x","journal-title":"Heart Fail Rev"},{"issue":"9","key":"6031_CR13","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1002\/ejhf.1182","volume":"20","author":"G Savarese","year":"2018","unstructured":"Savarese G, Carrero JJ, Pitt B et al (2018) Factors associated with underuse of mineralocorticoid receptor antagonists in heart failure with reduced ejection fraction: an analysis of 11 215 patients from the Swedish Heart Failure Registry. Eur J Heart Fail 20(9):1326\u20131334. https:\/\/doi.org\/10.1002\/ejhf.1182","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"6031_CR14","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.jacc.2018.04.070","volume":"72","author":"SJ Greene","year":"2018","unstructured":"Greene SJ, Butler J, Albert NM et al (2018) Medical therapy for heart failure with reduced ejection fraction: the CHAMP-HF registry. J Am Coll Cardiol 72(4):351\u2013366. https:\/\/doi.org\/10.1016\/j.jacc.2018.04.070","journal-title":"J Am Coll Cardiol"},{"issue":"5S","key":"6031_CR15","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","volume":"102","author":"Group KDIGOKDW","year":"2022","unstructured":"Group KDIGOKDW (2022) KDIGO 2022 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int 102(5S):S1\u2013S127. https:\/\/doi.org\/10.1016\/j.kint.2022.06.008","journal-title":"Kidney Int"},{"issue":"23","key":"6031_CR16","doi-asserted-by":"publisher","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","volume":"383","author":"GL Bakris","year":"2020","unstructured":"Bakris GL, Agarwal R, Anker SD et al (2020) Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes. N Engl J Med 383(23):2219\u20132229. https:\/\/doi.org\/10.1056\/NEJMoa2025845","journal-title":"N Engl J Med"},{"issue":"24","key":"6031_CR17","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","volume":"385","author":"B Pitt","year":"2021","unstructured":"Pitt B, Filippatos G, Agarwal R et al (2021) Cardiovascular events with finerenone in kidney disease and type 2 diabetes. N Engl J Med 385(24):2252\u20132263. https:\/\/doi.org\/10.1056\/NEJMoa2110956","journal-title":"N Engl J Med"},{"issue":"6","key":"6031_CR18","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","volume":"43","author":"R Agarwal","year":"2022","unstructured":"Agarwal R, Filippatos G, Pitt B et al (2022) Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 43(6):474\u2013484. https:\/\/doi.org\/10.1093\/eurheartj\/ehab777","journal-title":"Eur Heart J"},{"issue":"9","key":"6031_CR19","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/BF02155834","volume":"9","author":"SA Simpson","year":"1953","unstructured":"Simpson SA, Tait JF, Wettstein A, Neher R, Von Euw J, Reichstein T (1953) Isolation from the adrenals of a new crystalline hormone with especially high effectiveness on mineral metabolism. Experientia 9(9):333\u2013335. https:\/\/doi.org\/10.1007\/BF02155834","journal-title":"Experientia"},{"issue":"19","key":"6031_CR20","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJM195811062591907","volume":"259","author":"JT August","year":"1958","unstructured":"August JT, Nelson DH, Thorn GW (1958) Aldosterone. N Engl J Med 259(19):917\u2013923. https:\/\/doi.org\/10.1056\/NEJM195811062591907","journal-title":"N Engl J Med"},{"issue":"4","key":"6031_CR21","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1210\/endo-55-4-516","volume":"55","author":"G Sala","year":"1954","unstructured":"Sala G, Luetscher JA (1954) The effect of sodium-retaining corticoid, electrocortin, desoxycorticosterone, and cortisone on renal function and excretion of sodium and water in adrenalectomized rats. Endocrinology 55(4):516\u2013518. https:\/\/doi.org\/10.1210\/endo-55-4-516","journal-title":"Endocrinology"},{"issue":"5","key":"6031_CR22","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/0002-9343(72)90152-0","volume":"53","author":"D Feldman","year":"1972","unstructured":"Feldman D, Funder JW, Edelman IS (1972) Subcellular mechanisms in the action of adrenal steroids. Am J Med 53(5):545\u2013560. https:\/\/doi.org\/10.1016\/0002-9343(72)90152-0","journal-title":"Am J Med"},{"issue":"1","key":"6031_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ki.1981.97","volume":"20","author":"P Corvol","year":"1981","unstructured":"Corvol P, Claire M, Oblin ME, Geering K, Rossier B (1981) Mechanism of the antimineralocorticoid effects of spirolactones. Kidney Int 20(1):1\u20136. https:\/\/doi.org\/10.1038\/ki.1981.97","journal-title":"Kidney Int"},{"issue":"1","key":"6031_CR24","doi-asserted-by":"publisher","first-page":"T125","DOI":"10.1530\/JOE-16-0600","volume":"234","author":"P Kolkhof","year":"2017","unstructured":"Kolkhof P, B\u00e4rfacker L (2017) 30 years of the mineralocorticoid receptor: mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol 234(1):T125\u2013T140. https:\/\/doi.org\/10.1530\/JOE-16-0600","journal-title":"J Endocrinol"},{"issue":"4812","key":"6031_CR25","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1126\/science.3037703","volume":"237","author":"JL Arriza","year":"1987","unstructured":"Arriza JL, Weinberger C, Cerelli G et al (1987) Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor. Science 237(4812):268\u2013275. https:\/\/doi.org\/10.1126\/science.3037703","journal-title":"Science"},{"issue":"3","key":"6031_CR26","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1002\/cphy.c130044","volume":"4","author":"E Gomez-Sanchez","year":"2014","unstructured":"Gomez-Sanchez E, Gomez-Sanchez CE (2014) The multifaceted mineralocorticoid receptor. Compr Physiol 4(3):965\u2013994. https:\/\/doi.org\/10.1002\/cphy.c130044","journal-title":"Compr Physiol"},{"issue":"31","key":"6031_CR27","doi-asserted-by":"publisher","first-page":"2931","DOI":"10.1093\/eurheartj\/ehac299","volume":"43","author":"AK Pandey","year":"2022","unstructured":"Pandey AK, Bhatt DL, Cosentino F et al (2022) Non-steroidal mineralocorticoid receptor antagonists in cardiorenal disease. Eur Heart J 43(31):2931\u20132945. https:\/\/doi.org\/10.1093\/eurheartj\/ehac299","journal-title":"Eur Heart J"},{"issue":"8","key":"6031_CR28","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1038\/nrneph.2013.110","volume":"9","author":"NJ Brown","year":"2013","unstructured":"Brown NJ (2013) Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol 9(8):459\u2013469. https:\/\/doi.org\/10.1038\/nrneph.2013.110","journal-title":"Nat Rev Nephrol"},{"issue":"3","key":"6031_CR29","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/s0163-7258(99)00038-8","volume":"84","author":"MK Agarwal","year":"1999","unstructured":"Agarwal MK, Mirshahi M (1999) General overview of mineralocorticoid hormone action. Pharmacol Ther 84(3):273\u2013326. https:\/\/doi.org\/10.1016\/s0163-7258(99)00038-8","journal-title":"Pharmacol Ther"},{"key":"6031_CR30","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/bs.vh.2018.09.004","volume":"109","author":"PJ Fuller","year":"2019","unstructured":"Fuller PJ, Yang J, Young MJ (2019) Mechanisms of mineralocorticoid receptor signaling. Vitam Horm 109:37\u201368. https:\/\/doi.org\/10.1016\/bs.vh.2018.09.004","journal-title":"Vitam Horm"},{"key":"6031_CR31","doi-asserted-by":"publisher","unstructured":"Gomez-Sanchez CE, Gomez-Sanchez EP (2021) The mineralocorticoid receptor and the heart. Endocrinology 162(11). https:\/\/doi.org\/10.1210\/endocr\/bqab131","DOI":"10.1210\/endocr\/bqab131"},{"issue":"5","key":"6031_CR32","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1530\/EJE-09-1072","volume":"162","author":"A Wendler","year":"2010","unstructured":"Wendler A, Baldi E, Harvey BJ, Nadal A, Norman A, Wehling M (2010) Position paper: rapid responses to steroids: current status and future prospects. Eur J Endocrinol 162(5):825\u2013830. https:\/\/doi.org\/10.1530\/EJE-09-1072","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"6031_CR33","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1111\/j.1476-5381.2011.01366.x","volume":"163","author":"RD Feldman","year":"2011","unstructured":"Feldman RD, Gros R (2011) Unraveling the mechanisms underlying the rapid vascular effects of steroids: sorting out the receptors and the pathways. Br J Pharmacol 163(6):1163\u20131169. https:\/\/doi.org\/10.1111\/j.1476-5381.2011.01366.x","journal-title":"Br J Pharmacol"},{"issue":"7","key":"6031_CR34","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1210\/me.2004-0469","volume":"19","author":"C Grossmann","year":"2005","unstructured":"Grossmann C, Benesic A, Krug AW et al (2005) Human mineralocorticoid receptor expression renders cells responsive for nongenotropic aldosterone actions. Mol Endocrinol 19(7):1697\u20131710. https:\/\/doi.org\/10.1210\/me.2004-0469","journal-title":"Mol Endocrinol"},{"issue":"5","key":"6031_CR35","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrneph.2010.30","volume":"6","author":"M Briet","year":"2010","unstructured":"Briet M, Schiffrin EL (2010) Aldosterone: effects on the kidney and cardiovascular system. Nat Rev Nephrol 6(5):261\u2013273. https:\/\/doi.org\/10.1038\/nrneph.2010.30","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"6031_CR36","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1210\/endo-125-4-2224","volume":"125","author":"JW Funder","year":"1989","unstructured":"Funder JW, Pearce PT, Smith R, Campbell J (1989) Vascular type I aldosterone binding sites are physiological mineralocorticoid receptors. Endocrinology 125(4):2224\u20132226. https:\/\/doi.org\/10.1210\/endo-125-4-2224","journal-title":"Endocrinology"},{"issue":"2","key":"6031_CR37","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1161\/01.HYP.0000255636.11931.a2","volume":"49","author":"S Shibata","year":"2007","unstructured":"Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T (2007) Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 49(2):355\u2013364. https:\/\/doi.org\/10.1161\/01.HYP.0000255636.11931.a2","journal-title":"Hypertension"},{"key":"6031_CR38","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1146\/annurev-pharmtox-010814-124302","volume":"55","author":"A Lother","year":"2015","unstructured":"Lother A, Moser M, Bode C, Feldman RD, Hein L (2015) Mineralocorticoids in the heart and vasculature: new insights for old hormones. Annu Rev Pharmacol Toxicol 55:289\u2013312. https:\/\/doi.org\/10.1146\/annurev-pharmtox-010814-124302","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"4","key":"6031_CR39","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.110.983023","volume":"123","author":"D Fraccarollo","year":"2011","unstructured":"Fraccarollo D, Berger S, Galuppo P et al (2011) Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction. Circulation 123(4):400\u2013408. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.110.983023","journal-title":"Circulation"},{"issue":"4","key":"6031_CR40","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1161\/HYPERTENSIONAHA.110.163287","volume":"57","author":"A Lother","year":"2011","unstructured":"Lother A, Berger S, Gilsbach R et al (2011) Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function. Hypertension 57(4):746\u2013754. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.110.163287","journal-title":"Hypertension"},{"issue":"11","key":"6031_CR41","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1161\/CIRCRESAHA.108.174235","volume":"102","author":"M Caprio","year":"2008","unstructured":"Caprio M, Newfell BG, la Sala A et al (2008) Functional mineralocorticoid receptors in human vascular endothelial cells regulate intercellular adhesion molecule-1 expression and promote leukocyte adhesion. Circ Res 102(11):1359\u20131367. https:\/\/doi.org\/10.1161\/CIRCRESAHA.108.174235","journal-title":"Circ Res"},{"issue":"3","key":"6031_CR42","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1161\/01.res.71.3.503","volume":"71","author":"M Lomb\u00e8s","year":"1992","unstructured":"Lomb\u00e8s M, Oblin ME, Gasc JM, Baulieu EE, Farman N, Bonvalet JP (1992) Immunohistochemical and biochemical evidence for a cardiovascular mineralocorticoid receptor. Circ Res 71(3):503\u2013510. https:\/\/doi.org\/10.1161\/01.res.71.3.503","journal-title":"Circ Res"},{"issue":"1","key":"6031_CR43","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1161\/HYPERTENSIONAHA.114.04981","volume":"66","author":"R Urbanet","year":"2015","unstructured":"Urbanet R, Nguyen Dinh Cat A, Feraco A et al (2015) Adipocyte mineralocorticoid receptor activation leads to metabolic syndrome and induction of prostaglandin D2 synthase. Hypertension 66(1):149\u2013157. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.114.04981","journal-title":"Hypertension"},{"key":"6031_CR44","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.steroids.2014.05.001","volume":"91","author":"V Marzolla","year":"2014","unstructured":"Marzolla V, Armani A, Feraco A et al (2014) Mineralocorticoid receptor in adipocytes and macrophages: a promising target to fight metabolic syndrome. Steroids 91:46\u201353. https:\/\/doi.org\/10.1016\/j.steroids.2014.05.001","journal-title":"Steroids"},{"issue":"5","key":"6031_CR45","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/embo-reports\/kvd088","volume":"1","author":"P Gass","year":"2000","unstructured":"Gass P, Kretz O, Wolfer DP et al (2000) Genetic disruption of mineralocorticoid receptor leads to impaired neurogenesis and granule cell degeneration in the hippocampus of adult mice. EMBO Rep 1(5):447\u2013451. https:\/\/doi.org\/10.1093\/embo-reports\/kvd088","journal-title":"EMBO Rep"},{"issue":"2","key":"6031_CR46","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.mce.2011.07.020","volume":"350","author":"A Odermatt","year":"2012","unstructured":"Odermatt A, Kratschmar DV (2012) Tissue-specific modulation of mineralocorticoid receptor function by 11\u03b2-hydroxysteroid dehydrogenases: an overview. Mol Cell Endocrinol 350(2):168\u2013186. https:\/\/doi.org\/10.1016\/j.mce.2011.07.020","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"6031_CR47","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1152\/physrev.00011.2014","volume":"95","author":"BC Rossier","year":"2015","unstructured":"Rossier BC, Baker ME, Studer RA (2015) Epithelial sodium transport and its control by aldosterone: the story of our internal environment revisited. Physiol Rev 95(1):297\u2013340. https:\/\/doi.org\/10.1152\/physrev.00011.2014","journal-title":"Physiol Rev"},{"key":"6031_CR48","doi-asserted-by":"publisher","first-page":"111210","DOI":"10.1016\/j.mce.2021.111210","volume":"526","author":"EP Gomez-Sanchez","year":"2021","unstructured":"Gomez-Sanchez EP, Gomez-Sanchez CE (2021) 11\u03b2-Hydroxysteroid dehydrogenases: a growing multi-tasking family. Mol Cell Endocrinol 526:111210. https:\/\/doi.org\/10.1016\/j.mce.2021.111210","journal-title":"Mol Cell Endocrinol"},{"key":"6031_CR49","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3389\/fphar.2017.00313","volume":"8","author":"GH Tesch","year":"2017","unstructured":"Tesch GH, Young MJ (2017) Mineralocorticoid receptor signaling as a therapeutic target for renal and cardiac fibrosis. Front Pharmacol 8:313. https:\/\/doi.org\/10.3389\/fphar.2017.00313","journal-title":"Front Pharmacol"},{"issue":"2","key":"6031_CR50","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1053\/j.ackd.2014.08.003","volume":"22","author":"MH Schwenk","year":"2015","unstructured":"Schwenk MH, Hirsch JS, Bomback AS (2015) Aldosterone blockade in CKD: emphasis on pharmacology. Adv Chronic Kidney Dis 22(2):123\u2013132. https:\/\/doi.org\/10.1053\/j.ackd.2014.08.003","journal-title":"Adv Chronic Kidney Dis"},{"issue":"5","key":"6031_CR51","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1046\/j.1523-1755.2003.00929.x","volume":"63","author":"ER Blasi","year":"2003","unstructured":"Blasi ER, Rocha R, Rudolph AE, Blomme EA, Polly ML, McMahon EG (2003) Aldosterone\/salt induces renal inflammation and fibrosis in hypertensive rats. Kidney Int 63(5):1791\u20131800. https:\/\/doi.org\/10.1046\/j.1523-1755.2003.00929.x","journal-title":"Kidney Int"},{"issue":"4","key":"6031_CR52","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1172\/JCI118867","volume":"98","author":"EL Greene","year":"1996","unstructured":"Greene EL, Kren S, Hostetter TH (1996) Role of aldosterone in the remnant kidney model in the rat. J Clin Invest 98(4):1063\u20131068. https:\/\/doi.org\/10.1172\/JCI118867","journal-title":"J Clin Invest"},{"issue":"7035","key":"6031_CR53","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/s0140-6736(58)92163-9","volume":"1","author":"H Selye","year":"1958","unstructured":"Selye H (1958) Experimental production of endomyocardial fibrosis. Lancet 1(7035):1351\u20131353. https:\/\/doi.org\/10.1016\/s0140-6736(58)92163-9","journal-title":"Lancet"},{"issue":"6","key":"6031_CR54","first-page":"893","volume":"120","author":"CG Brilla","year":"1992","unstructured":"Brilla CG, Weber KT (1992) Mineralocorticoid excess, dietary sodium, and myocardial fibrosis. J Lab Clin Med 120(6):893\u2013901","journal-title":"J Lab Clin Med"},{"issue":"5","key":"6031_CR55","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1006\/jmcc.1993.1066","volume":"25","author":"CG Brilla","year":"1993","unstructured":"Brilla CG, Matsubara LS, Weber KT (1993) Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 25(5):563\u2013575. https:\/\/doi.org\/10.1006\/jmcc.1993.1066","journal-title":"J Mol Cell Cardiol"},{"issue":"3","key":"6031_CR56","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1161\/HYPERTENSIONAHA.109.131110","volume":"54","author":"AJ Rickard","year":"2009","unstructured":"Rickard AJ, Morgan J, Tesch G, Funder JW, Fuller PJ, Young MJ (2009) Deletion of mineralocorticoid receptors from macrophages protects against deoxycorticosterone\/salt-induced cardiac fibrosis and increased blood pressure. Hypertension 54(3):537\u2013543. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.109.131110","journal-title":"Hypertension"},{"issue":"5","key":"6031_CR57","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1016\/j.cjca.2023.01.013","volume":"39","author":"YL Wang","year":"2023","unstructured":"Wang YL, Ma XX, Li RG et al (2023) T-cell mineralocorticoid receptor deficiency attenuates pathologic ventricular remodelling after myocardial infarction. Can J Cardiol 39(5):593\u2013604. https:\/\/doi.org\/10.1016\/j.cjca.2023.01.013","journal-title":"Can J Cardiol"},{"issue":"1","key":"6031_CR58","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1093\/cvr\/cvp191","volume":"84","author":"A Hirata","year":"2009","unstructured":"Hirata A, Maeda N, Hiuge A et al (2009) Blockade of mineralocorticoid receptor reverses adipocyte dysfunction and insulin resistance in obese mice. Cardiovasc Res 84(1):164\u2013172. https:\/\/doi.org\/10.1093\/cvr\/cvp191","journal-title":"Cardiovasc Res"},{"issue":"17","key":"6031_CR59","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1161\/CIRCULATIONAHA.107.748640","volume":"117","author":"C Guo","year":"2008","unstructured":"Guo C, Ricchiuti V, Lian BQ et al (2008) Mineralocorticoid receptor blockade reverses obesity-related changes in expression of adiponectin, peroxisome proliferator-activated receptor-gamma, and proinflammatory adipokines. Circulation 117(17):2253\u20132261. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.107.748640","journal-title":"Circulation"},{"issue":"8","key":"6031_CR60","doi-asserted-by":"publisher","first-page":"2152","DOI":"10.1007\/s00125-011-2158-9","volume":"54","author":"JM Luther","year":"2011","unstructured":"Luther JM, Luo P, Kreger MT et al (2011) Aldosterone decreases glucose-stimulated insulin secretion in vivo in mice and in murine islets. Diabetologia 54(8):2152\u20132163. https:\/\/doi.org\/10.1007\/s00125-011-2158-9","journal-title":"Diabetologia"},{"issue":"4","key":"6031_CR61","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1007\/s00125-012-2814-8","volume":"56","author":"P Luo","year":"2013","unstructured":"Luo P, Dematteo A, Wang Z et al (2013) Aldosterone deficiency prevents high-fat-feeding-induced hyperglycaemia and adipocyte dysfunction in mice. Diabetologia 56(4):901\u2013910. https:\/\/doi.org\/10.1007\/s00125-012-2814-8","journal-title":"Diabetologia"},{"issue":"5","key":"6031_CR62","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1161\/HYPERTENSIONAHA.111.190223","volume":"59","author":"AM Briones","year":"2012","unstructured":"Briones AM, Nguyen Dinh Cat A, Callera GE et al (2012) Adipocytes produce aldosterone through calcineurin-dependent signaling pathways: implications in diabetes mellitus-associated obesity and vascular dysfunction. Hypertension 59(5):1069\u20131078. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.111.190223","journal-title":"Hypertension"},{"issue":"1","key":"6031_CR63","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/1758-5996-6-90","volume":"6","author":"T Bruder-Nascimento","year":"2014","unstructured":"Bruder-Nascimento T, da Silva MA, Tostes RC (2014) The involvement of aldosterone on vascular insulin resistance: implications in obesity and type 2 diabetes. Diabetol Metab Syndr 6(1):90. https:\/\/doi.org\/10.1186\/1758-5996-6-90","journal-title":"Diabetol Metab Syndr"},{"issue":"9","key":"6031_CR64","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1210\/jc.2006-0736","volume":"91","author":"C Catena","year":"2006","unstructured":"Catena C, Lapenna R, Baroselli S et al (2006) Insulin sensitivity in patients with primary aldosteronism: a follow-up study. J Clin Endocrinol Metab 91(9):3457\u20133463. https:\/\/doi.org\/10.1210\/jc.2006-0736","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"6031_CR65","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","volume":"6","author":"S Monticone","year":"2018","unstructured":"Monticone S, D\u2019Ascenzo F, Moretti C et al (2018) Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 6(1):41\u201350. https:\/\/doi.org\/10.1016\/S2213-8587(17)30319-4","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"6031_CR66","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.2337\/dc07-0525","volume":"30","author":"G Colussi","year":"2007","unstructured":"Colussi G, Catena C, Lapenna R, Nadalini E, Chiuch A, Sechi LA (2007) Insulin resistance and hyperinsulinemia are related to plasma aldosterone levels in hypertensive patients. Diabetes Care 30(9):2349\u20132354. https:\/\/doi.org\/10.2337\/dc07-0525","journal-title":"Diabetes Care"},{"issue":"4","key":"6031_CR67","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/ki.2014.348","volume":"87","author":"K Hosoya","year":"2015","unstructured":"Hosoya K, Minakuchi H, Wakino S et al (2015) Insulin resistance in chronic kidney disease is ameliorated by spironolactone in rats and humans. Kidney Int 87(4):749\u2013760. https:\/\/doi.org\/10.1038\/ki.2014.348","journal-title":"Kidney Int"},{"issue":"23","key":"6031_CR68","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1136\/hrt.2009.173344","volume":"95","author":"EM Freel","year":"2009","unstructured":"Freel EM, Tsorlalis IK, Lewsey JD et al (2009) Aldosterone status associated with insulin resistance in patients with heart failure\u2013data from the ALOFT study. Heart 95(23):1920\u20131924. https:\/\/doi.org\/10.1136\/hrt.2009.173344","journal-title":"Heart"},{"issue":"2","key":"6031_CR69","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/clpt.2009.117","volume":"86","author":"RB Felder","year":"2009","unstructured":"Felder RB, Yu Y, Zhang ZH, Wei SG (2009) Pharmacological treatment for heart failure: a view from the brain. Clin Pharmacol Ther 86(2):216\u2013220. https:\/\/doi.org\/10.1038\/clpt.2009.117","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"6031_CR70","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s11906-014-0427-y","volume":"16","author":"JB Koenig","year":"2014","unstructured":"Koenig JB, Jaffe IZ (2014) Direct role for smooth muscle cell mineralocorticoid receptors in vascular remodeling: novel mechanisms and clinical implications. Curr Hypertens Rep 16(5):427. https:\/\/doi.org\/10.1007\/s11906-014-0427-y","journal-title":"Curr Hypertens Rep"},{"issue":"9","key":"6031_CR71","doi-asserted-by":"publisher","first-page":"4803","DOI":"10.3390\/ijms23094803","volume":"23","author":"F Bioletto","year":"2022","unstructured":"Bioletto F, Bollati M, Lopez C et al (2022) Primary aldosteronism and resistant hypertension: a pathophysiological insight. Int J Mol Sci 23(9):4803. https:\/\/doi.org\/10.3390\/ijms23094803","journal-title":"Int J Mol Sci"},{"key":"6031_CR72","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.lfs.2017.05.002","volume":"179","author":"AP Harvey","year":"2017","unstructured":"Harvey AP, Montezano AC, Hood KY et al (2017) Vascular dysfunction and fibrosis in stroke-prone spontaneously hypertensive rats: the aldosterone-mineralocorticoid receptor-Nox1 axis. Life Sci 179:110\u2013119. https:\/\/doi.org\/10.1016\/j.lfs.2017.05.002","journal-title":"Life Sci"},{"key":"6031_CR73","doi-asserted-by":"publisher","first-page":"694758","DOI":"10.3389\/fendo.2021.694758","volume":"12","author":"MF Rossier","year":"2021","unstructured":"Rossier MF (2021) The cardiac mineralocorticoid receptor (MR): a therapeutic target against ventricular arrhythmias. Front Endocrinol (Lausanne) 12:694758. https:\/\/doi.org\/10.3389\/fendo.2021.694758","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"6031_CR74","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/ki.1982.14","volume":"21","author":"RJ Hen\u00e9","year":"1982","unstructured":"Hen\u00e9 RJ, Boer P, Koomans HA, Mees EJ (1982) Plasma aldosterone concentrations in chronic renal disease. Kidney Int 21(1):98\u2013101. https:\/\/doi.org\/10.1038\/ki.1982.14","journal-title":"Kidney Int"},{"issue":"10","key":"6031_CR75","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1161\/01.cir.100.10.1056","volume":"100","author":"RS McKelvie","year":"1999","unstructured":"McKelvie RS, Yusuf S, Pericak D et al (1999) Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 100(10):1056\u20131064. https:\/\/doi.org\/10.1161\/01.cir.100.10.1056","journal-title":"Circulation"},{"issue":"11","key":"6031_CR76","doi-asserted-by":"publisher","first-page":"1936","DOI":"10.1007\/s00125-004-1542-0","volume":"47","author":"KJ Schjoedt","year":"2004","unstructured":"Schjoedt KJ, Andersen S, Rossing P, Tarnow L, Parving HH (2004) Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate. Diabetologia 47(11):1936\u20131939. https:\/\/doi.org\/10.1007\/s00125-004-1542-0","journal-title":"Diabetologia"},{"issue":"7","key":"6031_CR77","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1016\/s0735-1097(01)01237-2","volume":"37","author":"M Cicoira","year":"2001","unstructured":"Cicoira M, Zanolla L, Rossi A et al (2001) Failure of aldosterone suppression despite angiotensin-converting enzyme (ACE) inhibitor administration in chronic heart failure is associated with ACE DD genotype. J Am Coll Cardiol 37(7):1808\u20131812. https:\/\/doi.org\/10.1016\/s0735-1097(01)01237-2","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"6031_CR78","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1136\/hrt.82.1.57","volume":"82","author":"RJ MacFadyen","year":"1999","unstructured":"MacFadyen RJ, Lee AF, Morton JJ, Pringle SD, Struthers AD (1999) How often are angiotensin II and aldosterone concentrations raised during chronic ACE inhibitor treatment in cardiac failure? Heart 82(1):57\u201361. https:\/\/doi.org\/10.1136\/hrt.82.1.57","journal-title":"Heart"},{"issue":"5","key":"6031_CR79","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jash.2012.07.003","volume":"6","author":"AS Bomback","year":"2012","unstructured":"Bomback AS, Rekhtman Y, Klemmer PJ, Canetta PA, Radhakrishnan J, Appel GB (2012) Aldosterone breakthrough during aliskiren, valsartan, and combination (aliskiren + valsartan) therapy. J Am Soc Hypertens 6(5):338\u2013345. https:\/\/doi.org\/10.1016\/j.jash.2012.07.003","journal-title":"J Am Soc Hypertens"},{"issue":"9","key":"6031_CR80","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1038\/ncpneph0575","volume":"3","author":"AS Bomback","year":"2007","unstructured":"Bomback AS, Klemmer PJ (2007) The incidence and implications of aldosterone breakthrough. Nat Clin Pract Nephrol 3(9):486\u2013492. https:\/\/doi.org\/10.1038\/ncpneph0575","journal-title":"Nat Clin Pract Nephrol"},{"issue":"2","key":"6031_CR81","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1161\/01.HYP.0000231338.41548.fc","volume":"48","author":"M Bochud","year":"2006","unstructured":"Bochud M, Nussberger J, Bovet P et al (2006) Plasma aldosterone is independently associated with the metabolic syndrome. Hypertension 48(2):239\u2013245. https:\/\/doi.org\/10.1161\/01.HYP.0000231338.41548.fc","journal-title":"Hypertension"},{"issue":"16","key":"6031_CR82","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1056\/NEJM198104163041602","volume":"304","author":"ML Tuck","year":"1981","unstructured":"Tuck ML, Sowers J, Dornfeld L, Kledzik G, Maxwell M (1981) The effect of weight reduction on blood pressure, plasma renin activity, and plasma aldosterone levels in obese patients. N Engl J Med 304(16):930\u2013933. https:\/\/doi.org\/10.1056\/NEJM198104163041602","journal-title":"N Engl J Med"},{"issue":"3281","key":"6031_CR83","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1126\/science.126.3281.1015","volume":"126","author":"CM Kagawa","year":"1957","unstructured":"Kagawa CM, Cella JA, Van Arman CG (1957) Action of new steroids in blocking effects of aldosterone and desoxycorticosterone on salt. Science 126(3281):1015\u20131016. https:\/\/doi.org\/10.1126\/science.126.3281.1015","journal-title":"Science"},{"issue":"3281","key":"6031_CR84","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1126\/science.126.3281.1016","volume":"126","author":"GW Liddle","year":"1957","unstructured":"Liddle GW (1957) Sodium diuresis induced by steroidal antagonists of aldosterone. Science 126(3281):1016\u20131018. https:\/\/doi.org\/10.1126\/science.126.3281.1016","journal-title":"Science"},{"issue":"1\u20132","key":"6031_CR85","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.mce.2003.10.005","volume":"217","author":"SM Garthwaite","year":"2004","unstructured":"Garthwaite SM, McMahon EG (2004) The evolution of aldosterone antagonists. Mol Cell Endocrinol 217(1\u20132):27\u201331. https:\/\/doi.org\/10.1016\/j.mce.2003.10.005","journal-title":"Mol Cell Endocrinol"},{"issue":"8","key":"6031_CR86","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1001\/jama.2013.905","volume":"309","author":"F Edelmann","year":"2013","unstructured":"Edelmann F, Wachter R, Schmidt AG et al (2013) Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 309(8):781\u2013791. https:\/\/doi.org\/10.1001\/jama.2013.905","journal-title":"JAMA"},{"issue":"15","key":"6031_CR87","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF et al (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370(15):1383\u20131392. https:\/\/doi.org\/10.1056\/NEJMoa1313731","journal-title":"N Engl J Med"},{"issue":"1","key":"6031_CR88","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1161\/CIRCULATIONAHA.114.013637","volume":"131","author":"P Rossignol","year":"2015","unstructured":"Rossignol P, Zannad F (2015) Regional differences in heart failure with preserved ejection fraction trials: when nephrology meets cardiology but east does not meet west. Circulation 131(1):7\u201310. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.114.013637","journal-title":"Circulation"},{"key":"6031_CR89","unstructured":"ClinicalTrials.gov (2023) Spironolactone in the treatment of heart failure. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04727073. Accessed 21 July 2023"},{"key":"6031_CR90","unstructured":"ClinicalTrials.gov (2023) Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure with Preserved Ejection Fraction. Available from https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02901184. Accessed 21 July 2023"},{"issue":"1","key":"6031_CR91","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10741-005-2345-1","volume":"10","author":"DA Sica","year":"2005","unstructured":"Sica DA (2005) Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis. Heart Fail Rev 10(1):23\u201329. https:\/\/doi.org\/10.1007\/s10741-005-2345-1","journal-title":"Heart Fail Rev"},{"key":"6031_CR92","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1001\/jama.1965.03090020077026","volume":"193","author":"E Clark","year":"1965","unstructured":"Clark E (1965) Spironolactone therapy and gynecomastia. JAMA 193:163\u2013164. https:\/\/doi.org\/10.1001\/jama.1965.03090020077026","journal-title":"JAMA"},{"key":"6031_CR93","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ijcard.2015.02.096","volume":"200","author":"PM Seferovic","year":"2015","unstructured":"Seferovic PM, Pelliccia F, Zivkovic I et al (2015) Mineralocorticoid receptor antagonists, a class beyond spironolactone\u2013focus on the special pharmacologic properties of eplerenone. Int J Cardiol 200:3\u20137. https:\/\/doi.org\/10.1016\/j.ijcard.2015.02.096","journal-title":"Int J Cardiol"},{"key":"6031_CR94","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ahj.2017.03.011","volume":"188","author":"D Vukadinovi\u0107","year":"2017","unstructured":"Vukadinovi\u0107 D, Lavall D, Vukadinovi\u0107 AN, Pitt B, Wagenpfeil S, B\u00f6hm M (2017) True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: a meta-analysis. Am Heart J 188:99\u2013108. https:\/\/doi.org\/10.1016\/j.ahj.2017.03.011","journal-title":"Am Heart J"},{"issue":"6","key":"6031_CR95","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"DN Juurlink","year":"2004","unstructured":"Juurlink DN, Mamdani MM, Lee DS et al (2004) Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 351(6):543\u2013551. https:\/\/doi.org\/10.1056\/NEJMoa040135","journal-title":"N Engl J Med"},{"issue":"11","key":"6031_CR96","doi-asserted-by":"publisher","first-page":"2056","DOI":"10.1002\/ejhf.1987","volume":"22","author":"JP Ferreira","year":"2020","unstructured":"Ferreira JP, Mogensen UM, Jhund PS et al (2020) Serum potassium in the PARADIGM-HF trial. Eur J Heart Fail 22(11):2056\u20132064. https:\/\/doi.org\/10.1002\/ejhf.1987","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"6031_CR97","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.jchf.2018.10.003","volume":"7","author":"G Savarese","year":"2019","unstructured":"Savarese G, Xu H, Trevisan M et al (2019) Incidence, predictors, and outcome associations of dyskalemia in heart failure with preserved, mid-range, and reduced ejection fraction. JACC Heart Fail 7(1):65\u201376. https:\/\/doi.org\/10.1016\/j.jchf.2018.10.003","journal-title":"JACC Heart Fail"},{"issue":"8","key":"6031_CR98","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1002\/ejhf.1757","volume":"22","author":"LB Cooper","year":"2020","unstructured":"Cooper LB, Benson L, Mentz RJ et al (2020) Association between potassium level and outcomes in heart failure with reduced ejection fraction: a cohort study from the Swedish Heart Failure Registry. Eur J Heart Fail 22(8):1390\u20131398. https:\/\/doi.org\/10.1002\/ejhf.1757","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"6031_CR99","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1002\/ejhf.2287","volume":"23","author":"M Trevisan","year":"2021","unstructured":"Trevisan M, Fu EL, Xu Y et al (2021) Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care. Eur J Heart Fail 23(10):1698\u20131707. https:\/\/doi.org\/10.1002\/ejhf.2287","journal-title":"Eur J Heart Fail"},{"issue":"41","key":"6031_CR100","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","volume":"43","author":"J Butler","year":"2022","unstructured":"Butler J, Anker SD, Lund LH et al (2022) Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. Eur Heart J 43(41):4362\u20134373. https:\/\/doi.org\/10.1093\/eurheartj\/ehac401","journal-title":"Eur Heart J"},{"issue":"11","key":"6031_CR101","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1002\/ejhf.2620","volume":"24","author":"RJ Janse","year":"2022","unstructured":"Janse RJ, Fu EL, Dahlstr\u00f6m U et al (2022) Use of guideline-recommended medical therapy in patients with heart failure and chronic kidney disease: from physician\u2019s prescriptions to patient\u2019s dispensations, medication adherence and persistence. Eur J Heart Fail 24(11):2185\u20132195. https:\/\/doi.org\/10.1002\/ejhf.2620","journal-title":"Eur J Heart Fail"},{"issue":"9","key":"6031_CR102","doi-asserted-by":"publisher","first-page":"1586","DOI":"10.1002\/ejhf.2635","volume":"24","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Ferreira JP, Rossignol P et al (2022) Effects of steroidal mineralocorticoid receptor antagonists on acute and chronic estimated glomerular filtration rate slopes in patients with chronic heart failure. Eur J Heart Fail 24(9):1586\u20131590. https:\/\/doi.org\/10.1002\/ejhf.2635","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"6031_CR103","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchf.2022.08.009","volume":"11","author":"G Savarese","year":"2023","unstructured":"Savarese G, Kishi T, Vardeny O et al (2023) Heart failure drug treatment-inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF). JACC Heart Fail 11(1):1\u201314. https:\/\/doi.org\/10.1016\/j.jchf.2022.08.009","journal-title":"JACC Heart Fail"},{"issue":"1","key":"6031_CR104","doi-asserted-by":"publisher","first-page":"F78","DOI":"10.1152\/ajprenal.00077.2007","volume":"293","author":"JM Mej\u00eda-Vilet","year":"2007","unstructured":"Mej\u00eda-Vilet JM, Ram\u00edrez V, Cruz C, Uribe N, Gamba G, Bobadilla NA (2007) Renal ischemia-reperfusion injury is prevented by the mineralocorticoid receptor blocker spironolactone. Am J Physiol Renal Physiol 293(1):F78-86. https:\/\/doi.org\/10.1152\/ajprenal.00077.2007","journal-title":"Am J Physiol Renal Physiol"},{"issue":"1","key":"6031_CR105","doi-asserted-by":"publisher","first-page":"R5","DOI":"10.1186\/ar2353","volume":"10","author":"SU Monrad","year":"2008","unstructured":"Monrad SU, Killen PD, Anderson MR, Bradke A, Kaplan MJ (2008) The role of aldosterone blockade in murine lupus nephritis. Arthritis Res Ther 10(1):R5. https:\/\/doi.org\/10.1186\/ar2353","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"6031_CR106","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1053\/j.ajkd.2007.10.040","volume":"51","author":"AS Bomback","year":"2008","unstructured":"Bomback AS, Kshirsagar AV, Amamoo MA, Klemmer PJ (2008) Change in proteinuria after adding aldosterone blockers to ACE inhibitors or angiotensin receptor blockers in CKD: a systematic review. Am J Kidney Dis 51(2):199\u2013211. https:\/\/doi.org\/10.1053\/j.ajkd.2007.10.040","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"6031_CR107","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1056\/NEJM200109203451215","volume":"345","author":"A Chrysostomou","year":"2001","unstructured":"Chrysostomou A, Becker G (2001) Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic renal disease. N Engl J Med 345(12):925\u2013926. https:\/\/doi.org\/10.1056\/NEJM200109203451215","journal-title":"N Engl J Med"},{"issue":"2","key":"6031_CR108","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/ncpneph1004","volume":"5","author":"AS Bomback","year":"2009","unstructured":"Bomback AS, Kshirsagar AV, Klemmer PJ (2009) Renal aspirin: will all patients with chronic kidney disease one day take spironolactone? Nat Clin Pract Nephrol 5(2):74\u201375. https:\/\/doi.org\/10.1038\/ncpneph1004","journal-title":"Nat Clin Pract Nephrol"},{"issue":"10","key":"6031_CR109","doi-asserted-by":"publisher","first-page":"CD007004","DOI":"10.1002\/14651858.CD007004.pub4","volume":"10","author":"EY Chung","year":"2020","unstructured":"Chung EY, Ruospo M, Natale P et al (2020) Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev 10(10):CD007004. https:\/\/doi.org\/10.1002\/14651858.CD007004.pub4","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"6031_CR110","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12882-016-0337-0","volume":"17","author":"G Currie","year":"2016","unstructured":"Currie G, Taylor AH, Fujita T et al (2016) Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol 17(1):127. https:\/\/doi.org\/10.1186\/s12882-016-0337-0","journal-title":"BMC Nephrol"},{"issue":"9","key":"6031_CR111","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1016\/j.clinthera.2015.05.508","volume":"37","author":"J Hou","year":"2015","unstructured":"Hou J, Xiong W, Cao L, Wen X, Li A (2015) Spironolactone add-on for preventing or slowing the progression of diabetic nephropathy: a meta-analysis. Clin Ther 37(9):2086-2103.e2010. https:\/\/doi.org\/10.1016\/j.clinthera.2015.05.508","journal-title":"Clin Ther"},{"issue":"6","key":"6031_CR112","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1016\/j.jacc.2013.09.056","volume":"63","author":"Y Matsumoto","year":"2014","unstructured":"Matsumoto Y, Mori Y, Kageyama S et al (2014) Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol 63(6):528\u2013536. https:\/\/doi.org\/10.1016\/j.jacc.2013.09.056","journal-title":"J Am Coll Cardiol"},{"issue":"4","key":"6031_CR113","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.kint.2018.08.034","volume":"95","author":"DM Charytan","year":"2019","unstructured":"Charytan DM, Himmelfarb J, Ikizler TA et al (2019) Safety and cardiovascular efficacy of spironolactone in dialysis-dependent ESRD (SPin-D): a randomized, placebo-controlled, multiple dosage trial. Kidney Int 95(4):973\u2013982. https:\/\/doi.org\/10.1016\/j.kint.2018.08.034","journal-title":"Kidney Int"},{"issue":"4","key":"6031_CR114","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.kint.2018.11.025","volume":"95","author":"F Hammer","year":"2019","unstructured":"Hammer F, Malzahn U, Donhauser J et al (2019) A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients. Kidney Int 95(4):983\u2013991. https:\/\/doi.org\/10.1016\/j.kint.2018.11.025","journal-title":"Kidney Int"},{"issue":"2","key":"6031_CR115","doi-asserted-by":"publisher","first-page":"CD013109","DOI":"10.1002\/14651858.CD013109.pub2","volume":"2","author":"T Hasegawa","year":"2021","unstructured":"Hasegawa T, Nishiwaki H, Ota E, Levack WM, Noma H (2021) Aldosterone antagonists for people with chronic kidney disease requiring dialysis. Cochrane Database Syst Rev 2(2):CD013109. https:\/\/doi.org\/10.1002\/14651858.CD013109.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"8","key":"6031_CR116","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1002\/cmdc.201200081","volume":"7","author":"L B\u00e4rfacker","year":"2012","unstructured":"B\u00e4rfacker L, Kuhl A, Hillisch A et al (2012) Discovery of BAY 94\u20138862: a nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases. ChemMedChem 7(8):1385\u20131403. https:\/\/doi.org\/10.1002\/cmdc.201200081","journal-title":"ChemMedChem"},{"issue":"36","key":"6031_CR117","doi-asserted-by":"publisher","first-page":"21876","DOI":"10.1074\/jbc.M115.657957","volume":"290","author":"L Amazit","year":"2015","unstructured":"Amazit L, Le Billan F, Kolkhof P et al (2015) Finerenone impedes aldosterone-dependent nuclear import of the mineralocorticoid receptor and prevents genomic recruitment of steroid receptor coactivator-1. J Biol Chem 290(36):21876\u201321889. https:\/\/doi.org\/10.1074\/jbc.M115.657957","journal-title":"J Biol Chem"},{"issue":"1","key":"6031_CR118","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","volume":"64","author":"P Kolkhof","year":"2014","unstructured":"Kolkhof P, Delbeck M, Kretschmer A et al (2014) Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol 64(1):69\u201378. https:\/\/doi.org\/10.1097\/FJC.0000000000000091","journal-title":"J Cardiovasc Pharmacol"},{"issue":"3","key":"6031_CR119","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/s40262-019-00820-x","volume":"59","author":"N Snelder","year":"2020","unstructured":"Snelder N, Heinig R, Drenth HJ et al (2020) Population pharmacokinetic and exposure-response analysis of finerenone: insights based on phase IIb data and simulations to support dose selection for pivotal trials in type 2 diabetes with chronic kidney disease. Clin Pharmacokinet 59(3):359\u2013370. https:\/\/doi.org\/10.1007\/s40262-019-00820-x","journal-title":"Clin Pharmacokinet"},{"issue":"4","key":"6031_CR120","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1161\/HYPERTENSIONAHA.117.10360","volume":"71","author":"J Grune","year":"2018","unstructured":"Grune J, Beyhoff N, Smeir E et al (2018) Selective mineralocorticoid receptor cofactor modulation as molecular basis for finerenone\u2019s antifibrotic activity. Hypertension 71(4):599\u2013608. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.117.10360","journal-title":"Hypertension"},{"issue":"6","key":"6031_CR121","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.kint.2017.12.016","volume":"93","author":"J Barrera-Chimal","year":"2018","unstructured":"Barrera-Chimal J, Estrela GR, Lechner SM et al (2018) The myeloid mineralocorticoid receptor controls inflammatory and fibrotic responses after renal injury via macrophage interleukin-4 receptor signaling. Kidney Int 93(6):1344\u20131355. https:\/\/doi.org\/10.1016\/j.kint.2017.12.016","journal-title":"Kidney Int"},{"issue":"5","key":"6031_CR122","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1161\/HYPERTENSIONAHA.116.08526","volume":"69","author":"L Lattenist","year":"2017","unstructured":"Lattenist L, Lechner SM, Messaoudi S et al (2017) Nonsteroidal mineralocorticoid receptor antagonist finerenone protects against acute kidney injury-mediated chronic kidney disease: role of oxidative stress. Hypertension 69(5):870\u2013878. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.116.08526","journal-title":"Hypertension"},{"key":"6031_CR123","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.3389\/fphar.2018.01131","volume":"9","author":"R Gonz\u00e1lez-Bl\u00e1zquez","year":"2018","unstructured":"Gonz\u00e1lez-Bl\u00e1zquez R, Somoza B, Gil-Ortega M et al (2018) Finerenone attenuates endothelial dysfunction and albuminuria in a chronic kidney disease model by a reduction in oxidative stress. Front Pharmacol 9:1131. https:\/\/doi.org\/10.3389\/fphar.2018.01131","journal-title":"Front Pharmacol"},{"issue":"1","key":"6031_CR124","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40618-021-01635-z","volume":"45","author":"V Marzolla","year":"2022","unstructured":"Marzolla V, Feraco A, Limana F, Kolkhof P, Armani A, Caprio M (2022) Class-specific responses of brown adipose tissue to steroidal and nonsteroidal mineralocorticoid receptor antagonists. J Endocrinol Invest 45(1):215\u2013220. https:\/\/doi.org\/10.1007\/s40618-021-01635-z","journal-title":"J Endocrinol Invest"},{"issue":"8","key":"6031_CR125","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1159\/000516213","volume":"52","author":"P Kolkhof","year":"2021","unstructured":"Kolkhof P, Hartmann E, Freyberger A et al (2021) Effects of finerenone combined with empagliflozin in a model of hypertension-induced end-organ damage. Am J Nephrol 52(8):642\u2013652. https:\/\/doi.org\/10.1159\/000516213","journal-title":"Am J Nephrol"},{"issue":"31","key":"6031_CR126","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","volume":"34","author":"B Pitt","year":"2013","unstructured":"Pitt B, Kober L, Ponikowski P et al (2013) Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94\u20138862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial. Eur Heart J 34(31):2453\u20132463. https:\/\/doi.org\/10.1093\/eurheartj\/eht187","journal-title":"Eur Heart J"},{"issue":"27","key":"6031_CR127","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","volume":"37","author":"G Filippatos","year":"2016","unstructured":"Filippatos G, Anker SD, B\u00f6hm M et al (2016) A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease. Eur Heart J 37(27):2105\u20132114. https:\/\/doi.org\/10.1093\/eurheartj\/ehw132","journal-title":"Eur Heart J"},{"issue":"9","key":"6031_CR128","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC et al (2015) Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA 314(9):884\u2013894. https:\/\/doi.org\/10.1001\/jama.2015.10081","journal-title":"JAMA"},{"issue":"11","key":"6031_CR129","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jchf.2022.07.013","volume":"10","author":"G Filippatos","year":"2022","unstructured":"Filippatos G, Anker SD, Pitt B et al (2022) Finerenone and heart failure outcomes by kidney function\/albuminuria in chronic kidney disease and diabetes. JACC Heart Fail 10(11):860\u2013870. https:\/\/doi.org\/10.1016\/j.jchf.2022.07.013","journal-title":"JACC Heart Fail"},{"issue":"6","key":"6031_CR130","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1161\/CIRCULATIONAHA.121.057983","volume":"145","author":"G Filippatos","year":"2022","unstructured":"Filippatos G, Anker SD, Agarwal R et al (2022) Finerenone reduces risk of incident heart failure in patients with chronic kidney disease and type 2 diabetes: analyses from the FIGARO-DKD trial. Circulation 145(6):437\u2013447. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.057983","journal-title":"Circulation"},{"issue":"2","key":"6031_CR131","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jacc.2021.04.079","volume":"78","author":"G Filippatos","year":"2021","unstructured":"Filippatos G, Bakris GL, Pitt B et al (2021) Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes. J Am Coll Cardiol 78(2):142\u2013152. https:\/\/doi.org\/10.1016\/j.jacc.2021.04.079","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"6031_CR132","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1002\/ejhf.2469","volume":"24","author":"G Filippatos","year":"2022","unstructured":"Filippatos G, Pitt B, Agarwal R et al (2022) Finerenone in patients with chronic kidney disease and type 2 diabetes with and without heart failure: a prespecified subgroup analysis of the FIDELIO-DKD trial. Eur J Heart Fail 24(6):996\u20131005. https:\/\/doi.org\/10.1002\/ejhf.2469","journal-title":"Eur J Heart Fail"},{"issue":"12","key":"6031_CR133","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.2337\/dc22-0294","volume":"45","author":"P Rossing","year":"2022","unstructured":"Rossing P, Anker SD, Filippatos G et al (2022) Finerenone in patients with chronic kidney disease and type 2 diabetes by sodium-glucose cotransporter 2 inhibitor treatment: the FIDELITY analysis. Diabetes Care 45(12):2991\u20132998. https:\/\/doi.org\/10.2337\/dc22-0294","journal-title":"Diabetes Care"},{"issue":"4","key":"6031_CR134","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40265-019-01073-5","volume":"79","author":"S Duggan","year":"2019","unstructured":"Duggan S (2019) Esaxerenone: first global approval. Drugs 79(4):477\u2013481. https:\/\/doi.org\/10.1007\/s40265-019-01073-5","journal-title":"Drugs"},{"issue":"1","key":"6031_CR135","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","volume":"75","author":"S Ito","year":"2020","unstructured":"Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, Yamakawa S (2020) Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN Study). Hypertension 75(1):51\u201358. https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.13569","journal-title":"Hypertension"},{"issue":"12","key":"6031_CR136","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.2215\/CJN.06870520","volume":"15","author":"S Ito","year":"2020","unstructured":"Ito S, Kashihara N, Shikata K et al (2020) Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial. Clin J Am Soc Nephrol 15(12):1715\u20131727. https:\/\/doi.org\/10.2215\/CJN.06870520","journal-title":"Clin J Am Soc Nephrol"},{"issue":"2","key":"6031_CR137","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1007\/s10157-020-01963-z","volume":"25","author":"T Wada","year":"2021","unstructured":"Wada T, Inagaki M, Yoshinari T et al (2021) Apararenone in patients with diabetic nephropathy: results of a randomized, double-blind, placebo-controlled phase 2 dose-response study and open-label extension study. Clin Exp Nephrol 25(2):120\u2013130. https:\/\/doi.org\/10.1007\/s10157-020-01963-z","journal-title":"Clin Exp Nephrol"},{"issue":"2","key":"6031_CR138","doi-asserted-by":"publisher","first-page":"e0193380","DOI":"10.1371\/journal.pone.0193380","volume":"13","author":"K Bamberg","year":"2018","unstructured":"Bamberg K, Johansson U, Edman K et al (2018) Preclinical pharmacology of AZD9977: a novel mineralocorticoid receptor modulator separating organ protection from effects on electrolyte excretion. PLoS One 13(2):e0193380. https:\/\/doi.org\/10.1371\/journal.pone.0193380","journal-title":"PLoS One"},{"key":"6031_CR139","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/bs.vh.2018.10.002","volume":"109","author":"SM Weldon","year":"2019","unstructured":"Weldon SM, Brown NF (2019) Inhibitors of aldosterone synthase. Vitam Horm 109:211\u2013239. https:\/\/doi.org\/10.1016\/bs.vh.2018.10.002","journal-title":"Vitam Horm"},{"key":"6031_CR140","doi-asserted-by":"publisher","first-page":"101918","DOI":"10.1016\/j.cpcardiol.2023.101918","volume":"48","author":"S Dogra","year":"2023","unstructured":"Dogra S, Shah S, Gitzel L et al (2023) Baxdrostat: a novel aldosterone synthase inhibitor for treatment resistant hypertension. Curr Probl Cardiol 48:101918. https:\/\/doi.org\/10.1016\/j.cpcardiol.2023.101918","journal-title":"Curr Probl Cardiol"},{"issue":"5","key":"6031_CR141","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1056\/NEJMoa2213169","volume":"388","author":"MW Freeman","year":"2023","unstructured":"Freeman MW, Halvorsen YD, Marshall W et al (2023) Phase 2 trial of baxdrostat for treatment-resistant hypertension. N Engl J Med 388(5):395\u2013405. https:\/\/doi.org\/10.1056\/NEJMoa2213169","journal-title":"N Engl J Med"},{"key":"6031_CR142","unstructured":"Bhatt D (2023) Efficacy and safety of baxdrostat in patients with uncontrolled hypertension - HALO [oral presentation]. Presented at American College of Cardiology Annual Scientific Session (ACC.23\/WCC), New Orleans, LA, 4\u20136 March 2023. Available from acc.org\/Latest-in-Cardiology\/Clinical-Trials\/2023\/03\/01\/23\/34\/halo. Accessed 19 Sep 2023"},{"issue":"16","key":"6031_CR143","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1016\/j.jacc.2016.02.033","volume":"67","author":"F Beygui","year":"2016","unstructured":"Beygui F, Cayla G, Roule V et al (2016) Early aldosterone blockade in acute myocardial infarction: the ALBATROSS randomized clinical trial. J Am Coll Cardiol 67(16):1917\u20131927. https:\/\/doi.org\/10.1016\/j.jacc.2016.02.033","journal-title":"J Am Coll Cardiol"},{"issue":"34","key":"6031_CR144","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1093\/eurheartj\/ehu164","volume":"35","author":"G Montalescot","year":"2014","unstructured":"Montalescot G, Pitt B, Lopez de Sa E et al (2014) Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study. Eur Heart J 35(34):2295\u20132302. https:\/\/doi.org\/10.1093\/eurheartj\/ehu164","journal-title":"Eur Heart J"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-023-06031-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-023-06031-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-023-06031-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T15:02:29Z","timestamp":1705330949000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-023-06031-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":144,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["6031"],"URL":"https:\/\/doi.org\/10.1007\/s00125-023-06031-1","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,21]]},"assertion":[{"value":"24 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"GS reports grants and personal fees from Vifor, grants and personal fees from Boehringer Ingelheim, grants and personal fees from AstraZeneca, personal fees from Servier, grants and personal fees from Novartis, grants and personal fees from Cytokinetics, personal fees from Medtronic, grants from Boston Scientific, grants and personal fees from Pharmacosmos, grants from Merck, grants from Bayer, personal fees from TEVA, personal fees from INTAS, personal fees from Abbott, outside the submitted work. FL declares that there are no relationships or activities that might bias, or be perceived to bias, his work. GF reports lecture fees and\/or that he is a committee member of trials and registries sponsored by Amgen, Bayer, Boehringer Ingelheim, Medtronic, Novartis, Servier, Impulse Dynamics and Vifor Pharma. He has received research support from the European Union. JB reports personal fees from Abbott, American Regent, Amgen, Applied Therapeutic, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Cardiac Dimension, Cardior, CVRx, Cytokinetics, Edwards, Element Science, Innolife, Impulse Dynamics, Imbria, Inventiva, Lexicon, Lilly, LivaNova, Janssen, Medtronics, Merck, Occlutech, Novartis, Novo Nordisk, Pfizer, Pharmacosmos, Pharmain, Roche, Sequana, SQ Innovation and Vifor. SDA reports grants and personal fees from Vifor and Abbott Vascular, and personal fees for consultancies, trial committee work and\/or lectures from Actimed, Amgen, Astra Zeneca, Bayer, Boehringer Ingelheim, Bioventrix, Brahms, Cardiac Dimensions, Cardior, Cordio, CVRx, Cytokinetics, Edwards, Farraday Pharmaceuticals, GSK, HeartKinetics, Impulse Dynamics, Novartis, Occlutech, Pfizer, Repairon, Sensible Medical, Servier, Vectorious and V-Wave. Named co-inventor of two patent applications regarding MR-proANP (DE 102007010834 & DE 102007022367), but he does not benefit personally from the related issued patents.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 relationships and activities"}},{"value":"All authors were responsible for drafting the article and reviewing it critically for important intellectual content. All authors approved the version to be published.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}}]}}